610 related articles for article (PubMed ID: 35651781)
1. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Deshpande A; Munoz J
Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
[TBL] [Abstract][Full Text] [Related]
3. Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
Wolska-Washer A; Robak T
Front Oncol; 2023; 13():1130595. PubMed ID: 37035197
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
5. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
Muñoz J; Sarosiek S; Castillo JJ
Oncologist; 2023 Apr; 28(4):309-318. PubMed ID: 36723874
[TBL] [Abstract][Full Text] [Related]
6. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
7. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Muñoz J; Paludo J; Sarosiek S; Castillo JJ
Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
[TBL] [Abstract][Full Text] [Related]
8. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
[TBL] [Abstract][Full Text] [Related]
9. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
10. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
Weaver AN; Jimeno A
Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
[TBL] [Abstract][Full Text] [Related]
11. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
Shirley M
Target Oncol; 2022 Jan; 17(1):69-84. PubMed ID: 34905129
[TBL] [Abstract][Full Text] [Related]
12. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
[TBL] [Abstract][Full Text] [Related]
13. A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
Moore DC; Thompson D
J Adv Pract Oncol; 2021 May; 12(4):439-447. PubMed ID: 34123480
[TBL] [Abstract][Full Text] [Related]
14. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
15. Zanubrutinib: past, present, and future.
Tam CS; Muñoz JL; Seymour JF; Opat S
Blood Cancer J; 2023 Sep; 13(1):141. PubMed ID: 37696810
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
17. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.
O'Brien SM; Brown JR; Byrd JC; Furman RR; Ghia P; Sharman JP; Wierda WG
Front Oncol; 2021; 11():720704. PubMed ID: 34858810
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
19. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib.
Charalambous A; Schwarzbich MA; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():133-168. PubMed ID: 30069629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]